Advertisement

Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study

  • Seiko Bun
  • Mayu YunokawaEmail author
  • Takahiro Ebata
  • Mayumi Kobayashi Kato
  • Tatsunori Shimoi
  • Tomoyasu Kato
  • Kenji Tamura
Original Article

Abstract

Purpose

The purpose of this study was to evaluate the real world situation and clarify the problem in initial treatment for elderly patients with ovarian cancer in Japan.

Methods

We used the ovarian cancer database, containing all patients diagnosed and treated with International Federation of Gynecology and Obstetrics Stage I–IV ovarian cancer at the National Cancer Center Hospital in Japan from June 2008 to April 2013. Patients were stratified into two groups based on age: an elderly group, aged 70 years or older, and a younger group, aged below 70 years. We retrospectively assessed the rate of receiving standard therapy, and the feasibility and safety of chemotherapy compared with younger patients.

Results

In total, 244 patients (elderly group, 36 patients; younger group, 208 patients) were analyzed. A significantly lower proportion of elderly patients than younger patients received standard therapy (15.7% vs. 32.5%, p = 0.026). Even for the elderly group, 95% patients underwent surgery in our institution. Conversely the rate of patients receiving nonstandard chemotherapy in the elderly group was significantly higher than in the younger group (30.5% vs. 9.6%, p = 0.01).

Conclusions

This study clarified the type of treatment being performed in the field, and the proportion of elderly ovarian cancer patients receiving standard therapy compared with younger patients in Japan. In addition, the actual situation of elderly patients in Japan might be different from that in Western countries. We need to evaluate the appropriate treatment for elderly patients in Japan.

Keywords

Elderly patients Ovarian cancer Standard therapy Relative dose intensity Feasibility 

Notes

Acknowledgements

We thank Colleen Elso, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. We would like to express our sincere thanks to all patients and investigators. The authors would like to thank Dr. Kan Yonemori, and Mr. Hiroyuki Terakado for supporting to make manuscript.

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):(9698):1331–1338.  https://doi.org/10.1016/S0140-6736(09)61157-0 CrossRefGoogle Scholar
  2. 2.
    Burger RA, Brady MF, Bookman MA et al (26):2473–2483.  https://doi.org/10.1056/NEJMoa1104390 CrossRefGoogle Scholar
  3. 3.
    Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484–2496.  https://doi.org/10.1056/NEJMoa1103799 CrossRefGoogle Scholar
  4. 4.
    Bun S, Yunokawa M, Ebata T et al (2016) Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacols 78(4):745–752.  https://doi.org/10.1007/s00280-016-3100-0 CrossRefGoogle Scholar
  5. 5.
    Freyer G, Geay JF, Touzet S et al (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16(11):1795–1800.  https://doi.org/10.1093/annonc/mdi368 CrossRefGoogle Scholar
  6. 6.
    Tredan O, Geay JF, Touzet S et al (2007) Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol 18(2):256–262.  https://doi.org/10.1093/annonc/mdl400 CrossRefGoogle Scholar
  7. 7.
    Falandry C, Weber B, Savoye AM et al (2013) Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol 24(11):2808–2813.  https://doi.org/10.1093/annonc/mdt360 CrossRefGoogle Scholar
  8. 8.
    von Gruenigen VE, Huang HQ, Beumer JH et al (2017) Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer—an NRG oncology/gynecologic oncology group study. Gynecol Oncol 144(3):459–467.  https://doi.org/10.1016/j.ygyno.2016.11.033 CrossRefGoogle Scholar
  9. 9.
    Fuh KC, Shin JY, Kapp DS et al (2015) Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol 136(3):491–497.  https://doi.org/10.1016/j.ygyno.2014.10.009 CrossRefGoogle Scholar
  10. 10.
    Pignata S, Breda E, Scambia G et al (2008) A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A multicentre Italian trial in ovarian cancer (MITO-5) study. Crit Rev Oncol/Hematol 66(3):229–236.  https://doi.org/10.1016/j.critrevonc.2007.12.005 CrossRefGoogle Scholar
  11. 11.
    Pignata S, Scambia G, Katsaros D et al (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396–405.  https://doi.org/10.1016/S1470-2045(14)70049-X CrossRefGoogle Scholar
  12. 12.
    Errico A (2014) Gynaecological cancer: MITO-7-a weekly regimen associated with a better quality of life for patients with advanced ovarian cancer. Nat Rev Clin Oncol 11(4):177.  https://doi.org/10.1038/nrclinonc.2014.45 CrossRefGoogle Scholar
  13. 13.
    Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines (2004) Int J Clin Oncol 9(Suppl 3):1–82Google Scholar
  14. 14.
    Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48(3):452–458.  https://doi.org/10.1038/bmt.2012.244 CrossRefGoogle Scholar
  15. 15.
    Wright JD, Ananth CV, Tsui J et al (2014) Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer 120(8):1246–1254.  https://doi.org/10.1002/cncr.28508 CrossRefGoogle Scholar
  16. 16.
    Fourcadier E, Tretarre B, Gras-Aygon C et al (2015) Under-treatment of elderly patients with ovarian cancer: a population based study. BMC cancer 15:937.  https://doi.org/10.1186/s12885-015-1947-9 CrossRefGoogle Scholar
  17. 17.
    Rauh-Hain JA, Melamed A, Wright A et al (2017) Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the National Cancer Database. JAMA Oncol 3(1):76–82.  https://doi.org/10.1001/jamaoncol.2016.4411 CrossRefGoogle Scholar
  18. 18.
    Katsumata N, Yasuda M, Isonishi S et al (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14(10):1020–1026.  https://doi.org/10.1016/S1470-2045(13)70363-2 CrossRefGoogle Scholar
  19. 19.
    Bandera EV, Lee VS, Rodriguez-Rodriguez L et al (2015) Impact of chemotherapy dosing on ovarian cancer survival according to body mass index. JAMA Oncol 1(6):737–745.  https://doi.org/10.1001/jamaoncol.2015.1796 CrossRefGoogle Scholar
  20. 20.
    Griffin DA, Penprase B, Klamerus JF (2012) Relative dose intensity–improving treatment and outcomes in early-stage breast cancer: a retrospective study. Oncol Nurs Forum 39(6):E459–467.  https://doi.org/10.1188/12.onf.e459-e467 CrossRefGoogle Scholar
  21. 21.
    Tanabe Y, Hashimoto K, Shimizu C et al (2013) Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 18(1):132–138.  https://doi.org/10.1007/s10147-011-0352-x CrossRefGoogle Scholar
  22. 22.
    Pignata S, Scambia G, Ferrandina G et al (2011) Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 29(27):3628–3635.  https://doi.org/10.1200/JCO.2010.33.8566 CrossRefGoogle Scholar
  23. 23.
    Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20):3323–3329.  https://doi.org/10.1200/JCO.2009.25.7519 CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Department of PharmacyNational Cancer Center HospitalTokyoJapan
  2. 2.Breast and Medical OncologyNational Cancer Center HospitalTokyoJapan
  3. 3.Department of Medical Oncology/Gynecologic OncologyCancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan
  4. 4.Department of GynecologyNational Cancer Center HospitalTokyoJapan
  5. 5.Department of Experimental TherapeuticsNational Cancer Center HospitalTokyoJapan

Personalised recommendations